Zacks: Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Consensus Target Price by Analysts

Shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price objective of $11.00 for the company and are forecasting that the company will post ($0.63) EPS for the current quarter, according to Zacks. Zacks has also assigned Sonoma Pharmaceuticals an industry rank of 180 out of 265 based on the ratings given to related companies.

SNOA has been the subject of a number of recent research reports. Benchmark initiated coverage on shares of Sonoma Pharmaceuticals in a report on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 target price for the company. Maxim Group set a $11.00 target price on shares of Sonoma Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 17th. Finally, Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th.

Shares of Sonoma Pharmaceuticals (SNOA) traded down $0.04 during trading on Wednesday, reaching $5.11. 13,906 shares of the company’s stock were exchanged, compared to its average volume of 22,596. The company has a market capitalization of $23.91, a P/E ratio of 2.87 and a beta of 1.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.37 and a quick ratio of 4.56. Sonoma Pharmaceuticals has a fifty-two week low of $4.16 and a fifty-two week high of $8.25.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Thursday, November 9th. The company reported ($0.67) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.08. The business had revenue of $4.33 million during the quarter, compared to the consensus estimate of $3.94 million. Sonoma Pharmaceuticals had a net margin of 47.68% and a negative return on equity of 43.23%. equities research analysts predict that Sonoma Pharmaceuticals will post -2.71 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Zacks: Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Consensus Target Price by Analysts” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/31/zacks-sonoma-pharmaceuticals-inc-snoa-given-11-00-consensus-target-price-by-analysts.html.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply